


Clinical Trials and Investigational Device Exemptions

**FDA Small Business
Regulatory Education for Industry (REdI)
Atlanta, GA
May 9, 2017**

Soma Kalb, Ph.D.
Director
Investigational Device Exemption Program
Clinical Trials Program
Office of Device Evaluation
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Innovation *and* Protection



Learning Objectives

- To understand the regulatory context of device clinical investigations
- To understand the requirements around off-label use
- To understand expanded access provisions

What is an IDE?

When is one needed?

Investigational Device Exemption

- Established in 21 CFR Part 812
- An IDE is a **regulatory submission** that permits clinical investigation of devices.
- FDA approval of an IDE is required for study of:
 - a **significant risk device** which is **not approved for the indication being studied**.

Common IDE Studies

- To **support marketing** application [PMA, HDE, 510(k) or *de novo*]
 - New device
 - New use of legally marketed device
- To gain **initial safety and effectiveness** information to support further study
- Sponsor-investigator studies of unapproved devices or new intended use of approved device (even if **no marketing** application planned)

FDA Decisions on IDE Application

- Made within **30 days**
- Decisions:
 - Approval
 - Approval with conditions
 - Disapproval
- **Disapproval** is appropriate when:
 - Probable risks to the subjects are not outweighed by the anticipated benefits and the importance of the knowledge to be gained
 - Study does not pose a reasonable scientific question and/or is not designed to collect data related to that scientific question

Key Provisions of the IDE Regulation

- Describes **applicability** of the IDE regulations
- Outlines the contents of the **IDE application**
- Describes **FDA actions** on IDE applications
- Describes **human subject protection** requirements
 - informed consent and IRB review
- Assigns **responsibilities** to all participants in clinical investigation – Monitoring, Records, Reporting

Can this happen?

Treatment

UNAPPROVED


APPROVED

Clinical
Use

**Unapproved
uses
of approved
devices??**

FDA and
IRB
Oversight

Research



Off-Label Use

What is Off-Label Use?

- Use of a **legally marketed device**
- In a manner inconsistent with product labeling
- Generally for a different indication


What is Labeling?

- **Defined** in 21 CFR 801
- **Explains:**
 - legally-marketed conditions of use (indications)
 - how to safely and effectively use the device
- **Includes:**
 - Packaging, User/Technical Manual
 - Indications for Use, Instructions for Use

Important to FDA device clearance/approval process

Striking Balance

- FDA does not interfere with good medical practice in best interest of patients
- Off-label use may lead to approvals for new or expanded indications
- Laws, regulations, and CDRH programs aim to leverage information about off-label use while protecting patients



Off-Label Use: Treatment


“Practice of Medicine”

*Nothing in this Act shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any **legally marketed device** to a patient for any condition or disease within a legitimate health care practitioner-patient relationship....*

From Section 1006 of the FD&C Act

Practice of Medicine

- Physicians **can** use approved devices in off-label manner to **treat** a patient within their best judgment
- **Physician Responsibilities:**
 - to be well informed about the product,
 - to base device use on firm scientific rationale and on sound medical evidence, and
 - to maintain records of the product's use and effects.
 - Institutional IRB policies may exist
- Prior approval from FDA not required



Off-label Use: Research

- Investigations **to determine safety and effectiveness of off-label use** fall under IDE regulation
 - If significant risk, requires submission of an IDE application to FDA
 - Subject to informed consent and IRB requirements

Research: On- vs. Off-Label

- **On-label**: A device “...that is used or investigated in accordance with the indications in the labeling...” is **exempt** from the IDE regulations (812.2(c)(2))
- Whether a study is on- or off-label may not be clear, for example
 - General to Specific
 - Study of group in “Warnings” section of labeling

General-to-Specific Example

- Surgical ablation devices may be cleared with a general indication of “ablation of cardiac tissue”
- **Question:** Is a study of the use of these devices for treating atrial fibrillation (AF) considered on-label or off-label?
- **Answer:** Off-label.

Treatment of AF would be considered a new intended use. The clinical endpoints for the general use can not be applied to the specific use (ablating tissue vs. health outcomes such as freedom from AF)


Off-Label Use vs. Research

- Clinical Trials Program receives many inquiries about what is research/investigation:
 - Device registries?
 - Surveillance?
 - “Retrospective” studies of off-label use?
- It might be an FDA-regulated investigation if:
 - There is a protocol
 - There are case report forms
 - Existence of the data collection effort is impacting treatment decisions

Real-World Evidence

- **Draft** guidance: *Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices*
- Active efforts to develop policy outlining regulatory requirements for generation of real-world evidence are underway
- Contact FDA for questions about whether a research activity is considered a FDA-regulated investigation

Expanded Access



What is Expanded Access?

- Use of an investigational device outside of a clinical study:
 - to save the life of a patient or to help a patient suffering from a serious disease or condition; and
 - for which no other alternative therapy exists.
- Three types
 - Emergency Use
 - Compassionate Use
 - Treatment Use

Resource:

[Expanded Access for Medical Devices](https://www.fda.gov/oc/ohrt/expanded-access-for-medical-devices)

Striking Balance

- All expanded access has patient protections in place to balance uncertainties of unapproved products
- We want to balance individual patient access with the need for evidence generation to support broader approval

What is Emergency Use?

- The shipment of investigational drugs or investigational devices,
- For the diagnosis, monitoring, or treatment of a serious disease or condition,
- In emergency situations.

Emergency Use

- **Criteria**
 - Life-threatening or serious disease or condition
 - includes sight-threatening and limb-threatening conditions as well as other situations involving risk of irreversible morbidity.
 - No alternative therapy exists
 - No time to obtain FDA approval
- Must be **reported** to FDA and IRB within 5 days of use

Emergency Use: Report Contents

- Device description
- Description of patient's condition and circumstances necessitating treatment
- Discussion of why alternative therapies were unsatisfactory
- Clarity on the urgency of the use
- **Patient protection measures** followed
- Outcome of procedure and any adverse events that occurred

Patient Protection Measures

- Informed consent from the patient or a legal representative;
- Clearance from the institution as specified by their policies;
- Concurrence of the IRB **chairperson**;
- An independent assessment from an uninvolved physician; and
- Authorization from the device manufacturer

What is Compassionate Use?

- **Criteria**
 - Serious disease or condition
 - No alternative treatment exists
 - Sufficient safety/effectiveness evidence
 - Its use should not interfere with the conduct of a clinical trial for the product
- Requires **prior approval** by FDA

Compassionate Use: Request Contents

- Device description
- Description of patient's condition and circumstances necessitating treatment
- Discussion:
 - why alternative therapies are unsatisfactory
 - why probable risk of device use is no greater than probable risk from disease/condition
- **Patient protection measures**

Compassionate Use is about Access

- Normally an unapproved device is only available for clinical study under an IDE
- Compassionate use allows *access* for **treatment**
- Compassionate use is not needed for devices commercially available in the US
 - “practice of medicine”
- Not a substitute for conducting a clinical study/marketing application

Conclusion

- FDA regulates clinical research of investigational medical devices
- Regulations balance the needs to advance research and provide access to novel products while protecting patient safety

Resources

- Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors – Medical Devices

www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm113709.htm

- Frequently Asked Questions About Medical Devices
- Significant Risk and Nonsignificant Risk Medical Device Studies

- Sponsor's Responsibilities For Significant Risk Device Investigations

www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm049859.htm

Resources

- Guidance: FDA Decisions for IDE Clinical Investigations
www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm279107.pdf
- Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with FDA Staff
www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM311176.pdf
- Device Advice: Expanded Access for Medical Devices
www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm051345.htm

Questions

Please complete the session survey:
surveymonkey.com/r/DEV-D1S04

Call To Action

- Engage in advancement of novel, innovative medical products that involve clinical research
- Be aware of regulatory responsibilities to advance science and protect patients along the way.